PKBO · Peak Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | - | $278.8K | $100.9K | $13.9K | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $112.2K | $108.6K | $70.3K | - | $553.0K | $371.2K | $713.1K | - | - | - |
| SG&A | $1.38M | $1.28M | $2.13M | - | $1.76M | $2.30M | $3.00M | - | - | - |
| Total Operating Expenses | $1.49M | $1.39M | $2.20M | - | $2.31M | $2.67M | $7.23M | - | $674.2K | $798.2K |
| D&A | - | - | $31.8K | - | - | - | $41.4K | - | - | - |
| Operating Income | ($1.49M) | ($1.39M) | ($2.20M) | - | ($2.03M) | ($2.67M) | ($7.22M) | - | ($674.2K) | ($798.2K) |
| Interest Expense | $1.22M | $449.0K | $323.1K | - | $1.22M | $0 | $4.0K | - | - | - |
| Income Tax | $0 | $0 | $0 | - | $0 | ($5.8K) | $0 | - | $8.1K | - |
| Net Income | $1.71M | ($2.08M) | ($2.43M) | - | $410.6K | ($5.94M) | ($6.77M) | - | ($171.0K) | ($321.9K) |
| EPS - Basic | $0.07 | ($0.09) | ($0.11) | - | $0.02 | ($0.29) | ($0.34) | - | ($0.02) | ($0.07) |
| EPS - Diluted | $0.06 | ($0.09) | ($0.11) | - | $0.01 | ($0.29) | ($0.34) | - | ($0.02) | ($0.07) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $862.1K | $235.8K | $68.6K | $381.6K | $94.4K | $214.4K | $564.2K | $654.9K | $76.0K | $44.7K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.36M | $5.47M | $5.79M | $5.86M | $5.68M | $5.13M | $4.86M | $3.62M | - | - |
| Current Assets | $1.54M | $1.33M | $1.56M | $2.37M | $1.26M | $1.51M | $2.36M | $3.23M | $136.7K | $215.2K |
| Total Assets | $1.64M | $1.43M | $1.75M | $2.60M | $1.51M | $1.80M | $2.68M | $7.53M | $57.99M | $57.80M |
| Current Liabilities | $22.40M | $24.03M | $22.28M | $20.52M | $18.71M | $18.01M | $16.82M | $10.80M | $2.09M | $1.48M |
| Long-term Debt | - | - | - | - | - | - | - | $0 | - | - |
| Total Liabilities | $22.54M | $24.03M | $22.28M | $20.75M | $19.07M | $21.11M | $17.05M | $15.62M | $2.39M | $2.03M |
| Stockholders' Equity | ($20.91M) | ($22.59M) | ($20.53M) | ($18.16M) | ($17.57M) | ($19.32M) | ($14.37M) | ($8.09M) | ($1.93M) | ($1.73M) |
| Retained Earnings | ($40.97M) | ($42.68M) | ($40.61M) | ($38.17M) | ($37.65M) | ($38.06M) | ($32.11M) | ($25.35M) | ($1.93M) | ($1.73M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.42M) | - | - | - | ($1.44M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $1.11M | - | - | - | $1.14M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -728.4% | -2646.0% | -52101.0% | - | - | - |
| EBITDA margin | - | - | - | - | - | - | -51802.1% | - | - | - |
| Net margin | - | - | - | - | 147.3% | -5890.3% | -48843.9% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | 198.3% | 367.8% | 5147.3% | - | - | - |
| SG&A / Revenue | - | - | - | - | 630.1% | 2278.2% | 21689.2% | - | - | - |
| Effective tax rate | 0.0% | - | - | - | 0.0% | - | - | - | - | - |
| Return on assets | 104.8% | -144.8% | -139.3% | - | 27.2% | -331.1% | -252.6% | - | -0.3% | -0.6% |
| Return on equity | -8.2% | 9.2% | 11.9% | - | -2.3% | 30.8% | 47.1% | - | 8.9% | 18.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.07 | 0.06 | 0.07 | 0.12 | 0.07 | 0.08 | 0.14 | 0.30 | 0.07 | 0.15 |
| Quick ratio | 0.07 | 0.06 | 0.07 | 0.12 | 0.07 | 0.08 | 0.14 | 0.30 | 0.07 | 0.15 |
| Cash ratio | 0.04 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.03 | 0.06 | 0.04 | 0.03 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | 0.00 | - | - |
| Debt / Assets | - | - | - | - | - | - | - | 0.00 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.2x | -3.1x | -6.8x | - | -1.7x | - | -1802.3x | - | - | - |
| Equity multiplier | -0.08 | -0.06 | -0.09 | -0.14 | -0.09 | -0.09 | -0.19 | -0.93 | -30.04 | -33.40 |
| Liabilities / Assets | 13.78 | 16.75 | 12.74 | 7.99 | 12.64 | 11.76 | 6.37 | 2.08 | 0.04 | 0.04 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.18 | 0.06 | 0.01 | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | -100.0% | -100.0% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 26.5% | 47.9% | 69.5% | - | -201.2% | -234.5% | -1565.7% | - | -546.0% | -619.2% |
| Net income growth (YoY) | 317.4% | 65.0% | 64.0% | - | - | -1746.4% | - | - | - | - |
| EPS growth (YoY) | 500.0% | 69.0% | 67.6% | - | - | -314.3% | - | - | - | - |
| EPS CAGR (3y) | 44.2% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -19.0% | -16.9% | -42.8% | -124.3% | -809.9% | -1016.3% | -920.5% | -303.6% | -77.7% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$4.00M totalGrant$4.00M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Peak Bio against the 5 most active filers in the same SIC group.